HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Ralf Sodian Sabine Daebritz Christoph Schmitz Bruno Reichart Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Sodian, R. Articles by Reichart, B. Search for Related Content PubMed PubMed Citation Articles by Sodian, R. Articles by Reichart, B. Related Collections Molecular biology Valve disease

---

Original Articles: Adult Cardiac

Use of Human Umbilical Cord Blood-Derived Progenitor Cells for Tissue-Engineered Heart Valves

^a Department of Cardiovascular Surgery, Ludwig-Maximilians-University, Munich, Germany
^c Institute of Anatomy, Ludwig-Maximilians-University, Munich, Germany
^b Department of Physiology, Charité University Medicine Berlin, Berlin, Germany

Accepted for publication November 19, 2009.

^_* Address correspondence to Dr Sodian, Department of Cardiac Surgery, Laboratory for Tissue Engineering and Cell Transplantation, Ludwig-Maximilians-University, Marchioninistr 15, Muenchen D-81377, Germany (Email: ralf.sodian{at}med.uni-muenchen.de).

Background: Tissue engineering of autologous heart valves with the potential to grow and to remodel represents a promising concept. Here we describe the use of cryopreserved umbilical cord blood-derived CD133⁺ cells as a single cell source for the tissue engineering of heart valves.

Methods: After expansion and differentiation of CD133⁺ cells, phenotypes were analyzed by immunohistochemistry and cryopreserved. Heart valve scaffolds fabricated from a biodegradable polymer (n = 8) were seeded with blood-derived myofibroblasts and subsequently coated with blood-derived endothelial cells. Afterward, the heart valve constructs were grown in a pulse duplicator system. Analysis of all heart valves, including histology, immunohistochemistry, electron microscopy, fluorescence imaging, and biochemical and biomechanical examination, was performed.

Results: The tissue-engineered heart valves showed endothelialized layered tissue formation including connective tissue between the inside and the outside of the scaffold. The notion of an intact endothelial phenotype was substantiated by fluorescence imaging studies of cellular nitric oxide production and Ca²⁺ signaling. Electron microscopy showed that the cells had grown into the pores and formed a confluent tissue layer. Biochemical examination showed extracellular matrix formation (77% ± 9% collagen of human pulmonary leaflet tissue [HPLT], 85% ± 61% glycosaminoglycans of HPLT and 67% ± 17% elastin of HPLT).

Conclusions: Importantly, this study demonstrates in vitro generation of viable human heart valves based on CD133⁺ cells derived from umbilical cord blood. These findings constitute a significant step forward in the development of new clinical strategies for the treatment of congenital defects.